

# Message from the President

Putting the Chugai Group mission statement and the Chugai Business Conduct Guidelines into practice to fulfill our social responsibility as a leading pharmaceutical company



The Chugai Group positioned 2009 as a year to make significant strides toward achieving the goals of its mid-term business plan, Sunrise 2012. To support our drive to become a top pharmaceutical company, we also drafted a new vision: To be a company that provides innovative medicines and services and consistently delivers new solutions to patients and healthcare providers around the world — a company where all innovation is for the benefit of patients. The Chugai Group is making concerted efforts to realize this vision.

## Achievements in 2009

---

The Chugai Group began cultivating biotechnology and antibody technologies in the 1980s, ahead of our competitors. Our strategic alliance with Roche also gave us access to a rich library of small-molecule compounds and allowed us to greatly expand our R&D pipeline. As a result, we have gained the top domestic market share in the fields of oncology and renal diseases. In 2009, solid growth in sales of products for bone and joint diseases improved our position in strategic therapeutic areas. In January 2009, Actemra, a humanized anti-human IL-6 receptor monoclonal antibody, was approved as RoActemra in the European Union for the additional indication of moderate to severe rheumatoid arthritis. In November, Avastin, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, received approval in Japan for the additional indication of, and dosage and administration for, non-small cell lung cancer. In addition to the further development of these and other growth drivers, we completed filings for approval of five projects and started phase I clinical trials for four others, to create the foundation for future growth.

## The Chugai Group's Approach to Social Responsibility

---

The Chugai Group strives to fulfill its social responsibility by using its mission statement as the starting point of business operations and by putting the Chugai Business Conduct Guidelines into practice. Chugai's stated mission is to dedicate itself to adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world. Going forward, we will do our utmost to contribute to improvements in patient care by using cutting-edge scientific technology to create a steady stream of innovative medicines with a particular focus on areas of unmet medical needs, where there is still great demand for new drugs and better treatments.

As Japan's leading pharmaceutical company in the field of oncology, Chugai conducts educational programs aimed at promoting patient-centered cancer care. In October 2009, we established the Chugai Academy for Advanced Oncology. The primary objective of this association is to promote deeper academic exchange between the world's top specialists in the field of oncology and healthcare providers who are playing a leading role in cutting-edge research and treatment of cancer in Japan. It will enable Chugai to contribute to the cancer treatment infrastructure in Japan as well as to the future advancement of cancer treatment from a standpoint different from our usual corporate activities.

The Chugai Group focuses its social contribution activities in the areas of healthcare, welfare, education, local communities, and the environment. In 2009, for example, we donated specially equipped welfare vehicles for the 25th consecutive year.

As environmental protection gains momentum worldwide, Chugai has taken the initiative to counter global warming with measures that include installing the latest energy-saving equipment and photovoltaic power generation equipment. We also recognize the need to place a higher priority on reducing greenhouse gas emissions. Therefore, in 2010, in addition to meeting the requirements of new laws and regulations that come into effect, we will formulate a mid-term greenhouse gas reduction plan centered on voluntary energy conservation measures to further advance environmental protection.

Chugai is committed to working even harder to meet the expectations of its stakeholders and promote the sustainable development of society by fulfilling its social responsibility as a leading pharmaceutical company. On behalf of the Chugai Group management team, I would like to thank all of you for your continued understanding and support of our efforts.



Osamu Nagayama  
Representative Director  
President, CEO and COO